{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:47:02Z","timestamp":1790804822158,"version":"4.1.0"},"reference-count":482,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":317,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007747","name":"University of Utah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229896"],"award-info":[{"award-number":["R01CA229896"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advanced Drug Delivery Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.addr.2025.115703","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:18:27Z","timestamp":1759537107000},"page":"115703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Recent advances in gene delivery for melanocyte-associated disorders"],"prefix":"10.1016","volume":"227","author":[{"given":"Tanya","family":"Chhibber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dekker C.","family":"Deacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Ghandehari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Judson-Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.mpsur.2021.11.005","article-title":"Physiology of the skin","volume":"40","author":"McKnight","year":"2022","journal-title":"Surgery (Oxford)"},{"key":"10.1016\/j.addr.2025.115703_bb0010","unstructured":"Lopez-Ojeda, W., et al., Anatomy, skin (integument), in StatPearls [Internet]. 2022, StatPearls Publishing."},{"key":"10.1016\/j.addr.2025.115703_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.878336","article-title":"Loss of \u2018epidermal melanin unit'integrity in human skin during melanoma-genesis","volume":"12","author":"Casalou","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0020","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.gene.2013.03.137","article-title":"History of gene therapy","volume":"525","author":"Wirth","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.addr.2025.115703_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120375","article-title":"Gene therapy: comprehensive overview and therapeutic applications","volume":"294","author":"Sayed","year":"2022","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/epigenomes7020009","article-title":"Critical considerations for investigating micrornas during tumorigenesis: a case study in conceptual and contextual nuances of miR-211-5p in melanoma","volume":"7","author":"Vand-Rajabpour","year":"2023","journal-title":"Epigenomes"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0035","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/v15030698","article-title":"Viral vectors in gene therapy: where do we stand in 2023?","volume":"15","author":"Lundstrom","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0040","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5114\/pdia.2013.33376","article-title":"Skin melanocytes: biology and development","volume":"30","author":"Cichorek","year":"2013","journal-title":"Adv. Dermatol. Allergol.\/Post\u0119py Dermatologii i Alergologii"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0045","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1096\/fj.06-6649rev","article-title":"Human skin pigmentation: melanocytes modulate skin color in response to stress","volume":"21","author":"Costin","year":"2007","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000518826","article-title":"Influence of ethnicities and skin color variations in different populations: a review","volume":"35","author":"Naik","year":"2022","journal-title":"Skin Pharmacol. Physiol."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110419","article-title":"Characterization of a melanocyte progenitor population in human interfollicular epidermis","volume":"38","author":"Michalak-Mi\u0107ka","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.addr.2025.115703_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1309557","article-title":"Biology of melanocytes in mammals","volume":"11","author":"Cui","year":"2023","journal-title":"Front. Cell Develop. Biol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1755-148X.2010.00803.x","article-title":"The cell biology of human hair follicle pigmentation","volume":"24","author":"Tobin","year":"2011","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0070","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1111\/j.0022-202X.2005.23959.x","article-title":"Changes in different melanocyte populations during hair follicle involution (catagen)","volume":"125","author":"Sharov","year":"2005","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0075","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1755-148X.2011.00855.x","article-title":"Melanocyte stem cells: a melanocyte reservoir in hair follicles for hair and skin pigmentation","volume":"24","author":"Nishimura","year":"2011","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0080","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1720","article-title":"Melanocyte stem cells in the skin: origin, biological characteristics, homeostatic maintenance and therapeutic potential","volume":"14","author":"Huang","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb0085","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S1357-2725(97)00013-7","article-title":"Melanin","volume":"29","author":"Riley","year":"1997","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0090","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1600-0749.2007.00362.x","article-title":"Quantification of Ca2+ binding to melanin supports the hypothesis that melanosomes serve a functional role in regulating calcium homeostasis","volume":"20","author":"Bush","year":"2007","journal-title":"Pigment Cell Res."},{"key":"10.1016\/j.addr.2025.115703_bb0095","series-title":"Seminars in cell & developmental biology","article-title":"Colorful DNA polymorphisms in humans","author":"Liu","year":"2013"},{"issue":"E1","key":"10.1016\/j.addr.2025.115703_bb0105","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1038\/skinbio.2011.4","article-title":"Determination of melanin synthetic pathways","volume":"131","author":"Hearing","year":"2011","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40257-021-00670-z","article-title":"Photoprotection for skin of color","volume":"23","author":"Tsai","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0115","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1242\/jcs.106.4.1323","article-title":"Contribution of melanogenic proteins to the heterogeneous pigmentation of human melanocytes","volume":"106","author":"Abdel-Malek","year":"1993","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41556-021-00740-8","article-title":"Human melanocyte development and melanoma dedifferentiation at single-cell resolution","volume":"23","author":"Belote","year":"2021","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.addr.2025.115703_bb0125","unstructured":"Schlessinger, D.I., M. Anoruo, and J. Schlessinger, Biochemistry, melanin, in StatPearls[Internet]. 2023, StatPearls Publishing."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jid.2021.06.018","article-title":"MC1R functions, expression, and implications for targeted therapy","volume":"142","author":"Guida","year":"2022","journal-title":"J. Invest. Dermatol."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb0135","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1167\/iovs.05-0834","article-title":"The ocular albinism type 1 (OA1) gene controls melanosome maturation and size","volume":"46","author":"Cortese","year":"2005","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/humu.10034","article-title":"New insights into ocular albinism type 1 (OA1): mutations and polymorphisms of the OA1 gene","volume":"19","author":"Oetting","year":"2002","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0145","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1038\/s41467-019-12733-1","article-title":"A novel mouse model demonstrates that oncogenic melanocyte stem cells engender melanoma resembling human disease","volume":"10","author":"Sun","year":"2019","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.stem.2017.09.001","article-title":"Melanocyte stem cell activation and translocation initiate cutaneous melanoma in response to UV exposure","volume":"21","author":"Moon","year":"2017","journal-title":"Cell Stem Cell"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2012.06.022","article-title":"Congenital melanocytic nevi: where are we now?: part II. Treatment options and approach to treatment","volume":"67","author":"Ibrahimi","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0160","first-page":"140","article-title":"12 - Lentigo Maligna Melanoma, in Pathology of Melanocytic Tumors","author":"Kiuru","year":"2019"},{"key":"10.1016\/j.addr.2025.115703_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.fsigen.2017.11.013","article-title":"Genetic determinants of freckle occurrence in the Spanish population: towards ephelides prediction from human DNA samples","volume":"33","author":"Hernando","year":"2018","journal-title":"Forensic Sci. Int. Genet."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0170","doi-asserted-by":"crossref","first-page":"S262","DOI":"10.1016\/j.jaad.2005.12.043","article-title":"Treatment of solar lentigines","volume":"54","author":"Ortonne","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0175","series-title":"Emery and Rimoin's Principles and Practice of Medical Genetics","first-page":"1","article-title":"Abnormalities of pigmentation","author":"Spritz","year":"2013"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0180","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2010.12.046","article-title":"Melasma: A comprehensive update: Part I","volume":"65","author":"Sheth","year":"2011","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0185","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jaad.2017.01.035","article-title":"Postinflammatory hyperpigmentation: a comprehensive overview: epidemiology, pathogenesis, clinical presentation, and noninvasive assessment technique","volume":"77","author":"Silpa-Archa","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0190","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.jaad.2019.08.064","article-title":"365-nm narrowband Wood's lamp for vitiligo and hypopigmentation disorders","volume":"83","author":"Bae","year":"2020","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0195","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jaad.2017.05.004","article-title":"Use of wood's lamp to diagnose progressive macular hypomelanosis","volume":"77","author":"Pflederer","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0200","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jaad.2023.12.040","article-title":"Vitiligo","volume":"90","author":"Manoj","year":"2024","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0205","series-title":"Clinical Slides Viewer","author":"UtahDERM","year":"2025"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0210","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jdcr.2017.10.005","article-title":"Piebaldism with multiple caf\u00e9-au-lait\u2013like hyperpigmented macules and inguinal freckling caused by a novel KIT mutation","volume":"4","author":"Nagaputra","year":"2018","journal-title":"JAAD Case Rep."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb0215","first-page":"797","article-title":"Pigmentation disorders: diagnosis and management","volume":"96","author":"Plensdorf","year":"2017","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.addr.2025.115703_bb0220","series-title":"Journal of the American Academy of Dermatology","article-title":"Vitiligo extent and distribution are associated with significant quality of life impairment","author":"Silverberg","year":"2013"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI185785","article-title":"Recent clinical and mechanistic insights into vitiligo offer new treatment options for cell-specific autoimmunity","volume":"135","author":"Ezzedine","year":"2025","journal-title":"J. Clin. Invest."},{"issue":"19\u201320","key":"10.1016\/j.addr.2025.115703_bb0230","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1101\/gad.329771.119","article-title":"Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities","volume":"33","author":"Rambow","year":"2019","journal-title":"Genes Dev."},{"key":"10.1016\/j.addr.2025.115703_bb0235","series-title":"StatPearls [Internet]","article-title":"Malignant melanoma [Updated year 2024]","author":"Heistein","year":"2024"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0240","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMra052166","article-title":"Melanoma","volume":"355","author":"Miller","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0245","article-title":"TERT promoter mutations and telomerase in melanoma","volume":"2022","author":"Guo","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.addr.2025.115703_bb0250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jare.2021.06.014","article-title":"Skin cancer biology and barriers to treatment: recent applications of polymeric micro\/nanostructures","volume":"36","author":"Khan","year":"2022","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.addr.2025.115703_bb0255","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2147\/CMAR.S155283","article-title":"MC1R variants as melanoma risk factors independent of at-risk phenotypic characteristics: a pooled analysis from the M-SKIP project","author":"Tagliabue","year":"2018","journal-title":"Cancer Manag. Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0260","doi-asserted-by":"crossref","first-page":"3541","DOI":"10.3390\/ijms24043541","article-title":"The complex interplay between nevi and melanoma: risk factors and precursors","volume":"24","author":"Shreberk-Hassidim","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"42","key":"10.1016\/j.addr.2025.115703_bb0265","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.1038\/onc.2017.189","article-title":"Melanocytic nevi and melanoma: unraveling a complex relationship","volume":"36","author":"Damsky","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0270","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","article-title":"The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia","volume":"9","author":"Bastian","year":"2014","journal-title":"Annu. Rev. Pathol.: Mech. Dis."},{"key":"10.1016\/j.addr.2025.115703_bb0275","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70385","article-title":"BRAFV600E induces reversible mitotic arrest in human melanocytes via microRNA-mediated suppression of AURKB","volume":"10","author":"McNeal","year":"2021","journal-title":"Elife"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0280","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jaad.2015.03.057","article-title":"Melanoma in situ: part II. Histopathology, treatment, and clinical management","volume":"73","author":"Higgins","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2015.04.014","article-title":"Melanoma in situ: part I. Epidemiology, screening, and clinical features","volume":"73","author":"Higgins","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0290","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1365-2133.2007.07830.x","article-title":"Gene expression profiling analysis of solar lentigo in relation to immunohistochemical characteristics","volume":"156","author":"Aoki","year":"2007","journal-title":"Br. J. Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0295","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.jid.2023.10.034","article-title":"Variants in the TERT gene increase the occurrence of solar lentigines by modifying telomerase expression exclusively in the skin","volume":"144","author":"Deecke","year":"2024","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0300","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1365-2133.2008.08963.x","article-title":"FGFR3 and PIK3CA mutations are involved in the molecular pathogenesis of solar lentigo","volume":"160","author":"Hafner","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0305","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0749.2004.00131.x","article-title":"Solar lentigines are strongly related to sun exposure in contrast to ephelides","volume":"17","author":"Bastiaens","year":"2004","journal-title":"Pigment Cell Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0310","doi-asserted-by":"crossref","DOI":"10.1111\/phpp.12953","article-title":"Characteristics of dermal vascularity in melasma and solar lentigo","volume":"40","author":"Hara","year":"2024","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0315","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/labinvest.2017.9","article-title":"The master role of microphthalmia-associated transcription factor in melanocyte and melanoma biology","volume":"97","author":"Kawakami","year":"2017","journal-title":"Lab. Investig."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/pcmr.12232","article-title":"Sun-induced freckling: ephelides and solar lentigines","volume":"27","author":"Praetorius","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0325","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/pcmr.12605","article-title":"Arginase-2, a miR-1299 target, enhances pigmentation in melasma by reducing melanosome degradation via senescence-induced autophagy inhibition","volume":"30","author":"Kim","year":"2017","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0330","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1038\/s41598-020-58911-w","article-title":"MicroRNA-141-3p and microRNA-200a-3p regulate \u03b1-melanocyte stimulating hormone-stimulated melanogenesis by directly targeting microphthalmia-associated transcription factor","volume":"10","author":"Itoh","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0335","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.domaniend.2009.10.004","article-title":"MicroRNA-25 functions in regulation of pigmentation by targeting the transcription factor MITF in alpaca (Lama pacos) skin melanocytes","volume":"38","author":"Zhu","year":"2010","journal-title":"Domest. Anim. Endocrinol."},{"issue":"15","key":"10.1016\/j.addr.2025.115703_bb0340","first-page":"3401","article-title":"microRNA regulation of skin pigmentation in fish","volume":"126","author":"Yan","year":"2013","journal-title":"J. Cell Sci."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0345","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1261\/rna.033977.112","article-title":"Coat color determination by miR-137 mediated down-regulation of microphthalmia-associated transcription factor in a mouse model","volume":"18","author":"Dong","year":"2012","journal-title":"Rna"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0350","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijwd.2017.05.002","article-title":"Laser treatment of medical skin disease in women","volume":"3","author":"LaRosa","year":"2017","journal-title":"Int. J. Women's Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0355","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/pcmr.12404","article-title":"Recent progress in melasma pathogenesis","volume":"28","author":"Lee","year":"2015","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.addr.2025.115703_bb0360","article-title":"Establishment and validation of evaluation models for post-inflammatory pigmentation abnormalities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3390\/jcm12031243","article-title":"Post-inflammatory hypopigmentation: review of the etiology, clinical manifestations, and treatment options","volume":"12","author":"Rao","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0370","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/biof.29","article-title":"Physiological factors that regulate skin pigmentation","volume":"35","author":"Yamaguchi","year":"2009","journal-title":"Biofactors"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0375","first-page":"1421","article-title":"Roles of inflammation factors in melanogenesis","volume":"21","author":"Fu","year":"2020","journal-title":"Mol. Med. Rep."},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb0380","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/medicina56070359","article-title":"Expression levels of inflammatory and oxidative stress-related genes in skin biopsies and their association with pityriasis alba","volume":"56","author":"Martinez-Fierro","year":"2020","journal-title":"Medicina"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0385","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archderm.140.2.210","article-title":"Propionibacterium acnes and the pathogenesis of progressive macular hypomelanosis","volume":"140","author":"Westerhof","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0390","unstructured":"Thomas MG, Zippin J, Brooks BP. Oculocutaneous Albinism and Ocular Albinism Overview. 2023 Apr 13. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews\u00ae [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK590568\/."},{"key":"10.1016\/j.addr.2025.115703_bb0395","series-title":"Albinism. StatPearls","author":"Federico","year":"2022"},{"key":"10.1016\/j.addr.2025.115703_bb0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-2-43","article-title":"Oculocutaneous albinism","volume":"2","author":"Gr\u00f8nskov","year":"2007","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0405","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1515\/biol-2016-0020","article-title":"MC1R gene variants involvement in human OCA phenotype","volume":"11","author":"Saleha","year":"2016","journal-title":"Open Life Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0410","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/med.21426","article-title":"Trends in regenerative medicine: repigmentation in vitiligo through melanocyte stem cell mobilization","volume":"37","author":"Birlea","year":"2017","journal-title":"Med. Res. Rev."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0415","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1038\/jid.2015.126","article-title":"Narrow band ultraviolet B treatment for human vitiligo is associated with proliferation, migration, and differentiation of melanocyte precursors","volume":"135","author":"Goldstein","year":"2015","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0420","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1097\/01.LAB.0000069521.42488.1B","article-title":"Immunopolarization of CD4+ and CD8+ T cells to type-1\u2013like is associated with melanocyte loss in human vitiligo","volume":"83","author":"Wa\u0144kowicz-Kali\u0144ska","year":"2003","journal-title":"Lab. Investig."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0425","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1038\/s41467-023-42714-4","article-title":"Rational design of a JAK1-selective siRNA inhibitor for the modulation of autoimmunity in the skin","volume":"14","author":"Tang","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.5021\/ad.2020.32.6.441","article-title":"The role of MicroRNAs in vitiligo: regulators and therapeutic targets","volume":"32","author":"Li","year":"2020","journal-title":"Ann. Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0435","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/pcmr.12878","article-title":"The enigma and challenges of vitiligo pathophysiology and treatment","volume":"33","author":"Abdel-Malek","year":"2020","journal-title":"Pigm. Cell Melanoma Res."},{"key":"10.1016\/j.addr.2025.115703_bb0440","first-page":"103","article-title":"Molecular basis of human piebaldism","author":"Spritz","year":"1994","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0445","doi-asserted-by":"crossref","DOI":"10.1111\/srt.13352","article-title":"Piebaldism with caf\u00e9-au-lait macules resulting from a novel mutation of KIT gene in a three-generation Chinese family","volume":"29","author":"Li","year":"2023","journal-title":"Skin Res. Technol."},{"issue":"11\u221212","key":"10.1016\/j.addr.2025.115703_bb0450","article-title":"Novel germline KIT variants in families with severe Piebaldism: case series and literature review","volume":"38","author":"Zhang","year":"2024","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.addr.2025.115703_bb0455","series-title":"KIT KIT proto-oncogene, receptor tyrosine kinase [ Homo sapiens (human)]","year":"2025"},{"key":"10.1016\/j.addr.2025.115703_bb0460","unstructured":"Shah, M., E. Patton, and D. Zedek, Piebaldism, in StatPearls [Internet]. 2023, StatPearls Publishing."},{"key":"10.1016\/j.addr.2025.115703_bb0465","article-title":"Novel pathogenic variants in KIT gene in three Chinese piebaldism patients","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.addr.2025.115703_bb0470","series-title":"Nevus of Ota and Ito","author":"Agarwal","year":"2020"},{"key":"10.1016\/j.addr.2025.115703_bb0475","series-title":"Pediatric Dermatology","first-page":"157","article-title":"Pigmentary disorders","author":"Simkin","year":"2021"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0480","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/pcmr.12452","article-title":"Genetic evolution of nevus of Ota reveals clonal heterogeneity acquiring BAP 1 and TP 53 mutations","volume":"29","author":"Vivancos","year":"2016","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0485","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/cup.12568","article-title":"Melanoma arising in a nevus of Ito: novel genetic mutations and a review of the literature on cutaneous malignant transformation of dermal melanocytosis","volume":"43","author":"Tse","year":"2016","journal-title":"J. Cutan. Pathol."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb0490","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw121","article-title":"De novo vs nevus-associated melanomas: differences in associations with prognostic indicators and survival","volume":"108","author":"Cymerman","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0495","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"Ca"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0500","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.clindermatol.2025.01.015","article-title":"Nodular Melanoma","volume":"43","author":"Gronbeck","year":"2025","journal-title":"Clin. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0505","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1586\/17469872.2.4.451","article-title":"Mechanism of UV-related carcinogenesis and its contribution to nevi\/melanoma","volume":"2","author":"Brozyna","year":"2007","journal-title":"Expert Rev. Dermat."},{"key":"10.1016\/j.addr.2025.115703_bb0510","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3389\/fonc.2020.00951","article-title":"Ultraviolet radiation and melanomagenesis: from mechanism to immunotherapy","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0515","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jid.2024.07.030","article-title":"Classification of cutaneous melanoma and melanocytic nevi with microRNA ratios is preserved in the acral melanoma subtype","volume":"145","author":"Deacon","year":"2025","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0520","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jid.2019.06.126","article-title":"MicroRNA ratios distinguish melanomas from nevi","volume":"140","author":"Torres","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0525","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/php.12749","article-title":"Melanoma chemoprevention: current status and future prospects","volume":"93","author":"Chhabra","year":"2017","journal-title":"Photochem. Photobiol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/cncr.31719","article-title":"Chemoprevention agents for melanoma: a path forward into phase 3 clinical trials","volume":"125","author":"Jeter","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0535","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/mt.2010.263","article-title":"MITF-siRNA formulation is a safe and effective therapy for human melasma","volume":"19","author":"Yi","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115703_bb0540","series-title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","first-page":"16","volume":"4","year":"2025"},{"key":"10.1016\/j.addr.2025.115703_bb0545","series-title":"A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940\u2013001)","first-page":"16","volume":"4","year":"2025"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0550","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3390\/ijms22083970","article-title":"Diversified stimuli-induced inflammatory pathways cause skin pigmentation","volume":"22","author":"Hossain","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb0555","series-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","article-title":"Mechanisms underlying post-inflammatory hyperpigmentation: Lessons from solar lentigo","author":"Cardinali","year":"2012"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0560","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12944-024-02130-z","article-title":"Comparative study of melasma in patients before and after treatment based on lipomics","volume":"23","author":"Zhu","year":"2024","journal-title":"Lipids Health Dis."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0565","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/exd.13915","article-title":"How hormones may modulate human skin pigmentation in melasma: an in vitro perspective","volume":"28","author":"Cario","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0570","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/ng1195-328","article-title":"Variants of the melanocyte\u2013stimulating hormone receptor gene are associated with red hair and fair skin in humans","volume":"11","author":"Valverde","year":"1995","journal-title":"Nat. Genet."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0575","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/modpathol.3880402","article-title":"Morphologic features of melanocytes, pigmented keratinocytes, and melanophages by in vivo confocal scanning laser microscopy","volume":"14","author":"Busam","year":"2001","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0580","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/jdv.19771","article-title":"Understanding the anatomy of dermoscopy of melanocytic skin tumours: correlation in vivo with line-field optical coherence tomography","volume":"38","author":"Soglia","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0585","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1001\/archdermatol.2009.388","article-title":"Morphologic features of melanophages under in vivo reflectance confocal microscopy","volume":"146","author":"Guitera","year":"2010","journal-title":"Arch. Dermatol."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb0590","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1111\/jocd.15827","article-title":"The role of reflectance confocal microscopy in the diagnosis and management of pigmentary disorders: a review","volume":"22","author":"Farabi","year":"2023","journal-title":"J. Cosmet. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0595","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/jid.2012.266","article-title":"Identification of miR-145 as a key regulator of the pigmentary process","volume":"133","author":"Dynoodt","year":"2013","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0600","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/pcmr.12179","article-title":"Novel inhibitory function of miR-125b in melanogenesis","volume":"27","author":"Kim","year":"2014","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0605","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijwd.2017.01.004","article-title":"A review of laser and light therapy in melasma","volume":"3","author":"Trivedi","year":"2017","journal-title":"Int. J. Women's Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0615","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2147\/CCID.S498987","article-title":"Self-delivering RNAi compounds for reduction of hyperpigmentation","author":"Maxwell","year":"2024","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0620","unstructured":"Givler, D.N., H.M. Saleh, and A. Givler, Pityriasis alba, in StatPearls [internet]. 2024, StatPearls Publishing."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0625","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4103\/cdr.cdr_62_23","article-title":"Profile of micronutrients in patients presenting with Pityriasis Alba in a tertiary care center: a case\u2013control study","volume":"8","author":"Shashikumar","year":"2024","journal-title":"Clin. Dermatol. Rev."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0630","first-page":"66","article-title":"Pityriasis alba revisited: perspectives on an enigmatic disorder of childhood","volume":"87","author":"Jadotte","year":"2011","journal-title":"Cutis"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0635","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2230.2008.03038.x","article-title":"Clinical and histopathological characteristics of pityriasis alba","volume":"34","author":"In","year":"2009","journal-title":"Clin. Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0640","article-title":"Double-blind, placebo-controlled, randomized study comparing 0.0003% calcitriol with 0.1% tacrolimus ointments for the treatment of endemic pityriasis alba","volume":"2012","author":"Moreno-Cruz","year":"2012","journal-title":"Dermatol. Res. Pract."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0645","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/pde.15252","article-title":"Adolescent extra-truncal progressive macular hypomelanosis","volume":"40","author":"Paquette","year":"2023","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0650","series-title":"Treating and Preventing Postinflammatory Hypo-and Hyperpigmentation","author":"Andrus","year":"2023"},{"key":"10.1016\/j.addr.2025.115703_bb0655","unstructured":"Sekhon, R., F. Rocha Cabrero, and J. Deibel, Nystagmus types. StatPearls. 2023, StatPearls Publishing. https:\/\/www. ncbi. nlm. nih. gov\/pubmed\/30969533."},{"key":"10.1016\/j.addr.2025.115703_bb0660","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s12013-014-0152-9","article-title":"In silico analysis of miRNA-mediated gene regulation in OCA and OA genes","volume":"70","author":"Kamaraj","year":"2014","journal-title":"Cell Biochem. Biophys."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0665","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.1038\/s41598-020-60931-5","article-title":"Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7","volume":"10","author":"Romano","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115703_bb0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-018-0619-7","article-title":"MiR-876-5p modulates head and neck squamous cell carcinoma metastasis and invasion by targeting vimentin","volume":"18","author":"Dong","year":"2018","journal-title":"Cancer Cell Int."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0675","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40259-017-0243-4","article-title":"Advances in the application and impact of microRNAs as therapies for skin disease","volume":"31","author":"Lawrence","year":"2017","journal-title":"BioDrugs"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0680","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4161\/rna.28865","article-title":"MicroRNA-218 inhibits melanogenesis by directly suppressing microphthalmia-associated transcription factor expression","volume":"11","author":"Guo","year":"2014","journal-title":"RNA Biol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0685","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.survophthal.2020.10.007","article-title":"Current and emerging treatments for albinism","volume":"66","author":"Liu","year":"2021","journal-title":"Surv. Ophthalmol."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb0690","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3390\/biom14101284","article-title":"Modulating OCA2 expression as a promising approach to enhance skin brightness and reduce dark spots","volume":"14","author":"Cho","year":"2024","journal-title":"Biomolecules"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0695","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1038\/mt.2009.112","article-title":"AAV-mediated tyrosinase gene transfer restores melanogenesis and retinal function in a model of oculo-cutaneous albinism type I (OCA1)","volume":"17","author":"Gargiulo","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115703_bb0700","unstructured":"3\/7\/2025; Available from: https:\/\/techtransfer.cancer.gov\/available-technologies?abstract=TAB-4991."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0705","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1089\/crispr.2021.0110","article-title":"CRISPR-AsCas12a efficiently corrects a GPR143 intronic mutation in induced pluripotent stem cells from an ocular albinism patient","volume":"5","author":"Torriano","year":"2022","journal-title":"The CRISPR J."},{"key":"10.1016\/j.addr.2025.115703_bb0710","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ebiom.2018.09.041","article-title":"Functional validation of the albinism-associated tyrosinase T373K SNP by CRISPR\/Cas9-mediated homology-directed repair (HDR) in rabbits","volume":"36","author":"Song","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.addr.2025.115703_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.964982","article-title":"MicroRNAs: emerging players in the pathogenesis of vitiligo","volume":"10","author":"Yu","year":"2022","journal-title":"Front. Cell Develop. Biol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0720","first-page":"742","article-title":"MicroRNA-155 is dysregulated in the skin of patients with vitiligo and inhibits melanogenesis-associated genes in melanocytes and keratinocytes","volume":"96","author":"Tankov","year":"2016","journal-title":"Acta Derm. Venereol."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0725","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/j.ymthe.2022.04.019","article-title":"RNAi-based modulation of IFN-\u03b3 signaling in skin","volume":"30","author":"Tang","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0730","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/09546630802155057","article-title":"The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial","volume":"20","author":"Esfandiarpour","year":"2009","journal-title":"J. Dermatol. Treat."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0735","doi-asserted-by":"crossref","DOI":"10.1002\/ski2.404","article-title":"Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: a randomised controlled trial secondary analysis at 3 years","volume":"4","author":"Harris","year":"2024","journal-title":"Skin Health and Disease"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0740","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/bjd\/ljae478","article-title":"Vitiligo is associated with lower body mass index: a retrospective case\u2013control study","volume":"192","author":"Sharifzadeh","year":"2025","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0745","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jdv.16927","article-title":"Patients' perspective on current treatments and demand for novel treatments in vitiligo","volume":"35","author":"Narayan","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb0750","first-page":"2706","article-title":"Peripheral blood of vitiligo patients-derived exosomal miR-21-5p inhibits melanocytes melanogenesis via targeting SATB1","volume":"51","author":"Guo","year":"2022","journal-title":"Iran. J. Public Health"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0755","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s10038-021-00993-z","article-title":"LncRNA-mRNA co-expression network revealing the regulatory roles of lncRNAs in melanogenesis in vitiligo","volume":"67","author":"Pang","year":"2022","journal-title":"J. Hum. Genet."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0760","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1346-8138.2012.01583.x","article-title":"Piebaldism","volume":"40","author":"Oiso","year":"2013","journal-title":"J. Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0765","first-page":"397","article-title":"Disorders of hyperpigmentation and melanocytes","volume":"2","author":"Gibbs","year":"2007","journal-title":"Neonatal Dermatol."},{"key":"10.1016\/j.addr.2025.115703_bb0770","unstructured":"Nevus of Ota and Ito. 3\/6\/2025]; Available from: https:\/\/www.aocd.org\/page\/NevusofOtaandIto."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0775","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1365-2133.2010.10014.x","article-title":"Long-term results of noncultured epidermal cellular grafting in vitiligo, halo naevi, piebaldism and naevus depigmentosus","volume":"163","author":"Van Geel","year":"2010","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0780","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1600-0749.1999.tb00510.x","article-title":"Horizontal and vertical pigment spread into surrounding piebald epidermis and hair follicles after suction blister epidermal grafting","volume":"12","author":"Horikawa","year":"1999","journal-title":"Pigment Cell Res."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0785","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.jid.5700639","article-title":"Piebald trait: implication of kit mutation on in vitro melanocyte survival and on the clinical application of cultured epidermal autografts","volume":"127","author":"Bondanza","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0790","doi-asserted-by":"crossref","first-page":"463","DOI":"10.2340\/0001555577463466","article-title":"Epidermal sheet grafts for repigmentation of vitiligo and piebaldism, with a review of surgical techniques","volume":"77","author":"Olsson","year":"1997","journal-title":"Acta Derm. Venereol."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb0795","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1346-8138.2003.tb00492.x","article-title":"Autologous punch grafting for repigmentation in piebaldism","volume":"30","author":"Garg","year":"2003","journal-title":"J. Dermatol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0800","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1046\/j.1365-2133.1998.02508.x","article-title":"Repigmentation of leucodermic defects in piebaldism by dermabrasion and thin split-thickness skin grafting in combination with minigrafting","volume":"139","author":"Njoo and Westerhof","year":"1998","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0805","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1067\/mjd.2002.119670","article-title":"Medical pearl: DHA application for camouflaging segmental vitiligo and piebald lesions","volume":"47","author":"Suga","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0810","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.0007-0963.2004.05500.x","article-title":"Permanent repigmentation of piebaldism by erbium: YAG laser and autologous cultured epidermis","volume":"150","author":"Guerra","year":"2004","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0815","first-page":"5505","article-title":"Intranasal sirna targeting c-kit reduces airway inflammation in experimental allergic asthma","volume":"7","author":"Wu","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb0820","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1038\/s41417-022-00437-6","article-title":"Targeting GNAQ\/11 through PKC inhibition in uveal melanoma","volume":"29","author":"Lietman","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0825","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/pcmr.12933","article-title":"Strategies in DNA vaccine for melanoma cancer","volume":"34","author":"Rezaei","year":"2021","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0830","doi-asserted-by":"crossref","first-page":"341","DOI":"10.4103\/ijd.IJD_323_20","article-title":"Gene therapy and its application in dermatology","volume":"65","author":"Sarkar","year":"2020","journal-title":"Indian J. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0835","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a015149","article-title":"Gene therapy for skin diseases","volume":"4","author":"Gorell","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0840","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/mps4010010","article-title":"Recent advances in miRNA delivery systems","volume":"4","author":"Dasgupta","year":"2021","journal-title":"Methods and Protocols"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0845","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1389200218666170222150555","article-title":"Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers","volume":"18","author":"Das Kurmi","year":"2017","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.addr.2025.115703_bb0850","first-page":"1","article-title":"Enhancement strategies for transdermal drug delivery systems: current trends and applications","author":"Ramadon","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb0855","doi-asserted-by":"crossref","first-page":"967","DOI":"10.4155\/tde-2017-0075","article-title":"Potential enhancement and targeting strategies of polymeric and lipid-based nanocarriers in dermal drug delivery","volume":"8","author":"Kahraman","year":"2017","journal-title":"Ther. Deliv."},{"issue":"14","key":"10.1016\/j.addr.2025.115703_bb0860","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411289","article-title":"Melanin's journey from melanocytes to keratinocytes: uncovering the molecular mechanisms of melanin transfer and processing","volume":"24","author":"Bento-Lopes","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040377","article-title":"Understanding the melanocyte distribution in human epidermis: an agent-based computational model approach","volume":"7","author":"Thingnes","year":"2012","journal-title":"PLoS One"},{"issue":"14","key":"10.1016\/j.addr.2025.115703_bb0870","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7528","article-title":"Melanin content in melanoma metastases affects the outcome of radiotherapy","volume":"7","author":"Bro\u017cyna","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0875","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/bcpt.12748","article-title":"Pharmacological properties of melanin and its function in health","volume":"120","author":"ElObeid","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0880","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1152\/physrev.00044.2003","article-title":"Melanin pigmentation in mammalian skin and its hormonal regulation","volume":"84","author":"Slominski","year":"2004","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb0885","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ijc.24005","article-title":"Inhibitors of melanogenesis increase toxicity of cyclophosphamide and lymphocytes against melanoma cells","volume":"124","author":"Slominski","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.addr.2025.115703_bb0890","doi-asserted-by":"crossref","first-page":"113586","DOI":"10.1016\/j.jconrel.2025.113586","article-title":"Transdermal delivery of Ultradeformable cationic liposomes complexed with miR211\u20135p (UCL-211) stabilizes BRAFV600E+ melanocytic nevi","volume":"381","author":"Chhibber","year":"2025","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb0895","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.omtn.2017.09.009","article-title":"CRISPR\/Cas9 genome-editing system in human stem cells: current status and future prospects","volume":"9","author":"Zhang","year":"2017","journal-title":"Mol. Therapy Nucleic Acids"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0900","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","article-title":"Recent advances in CRISPR\/Cas9 delivery approaches for therapeutic gene editing of stem cells","volume":"19","author":"Lotfi","year":"2023","journal-title":"Stem Cell Rev. Rep."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0905","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejcb.2015.12.001","article-title":"Tight junctions form a barrier in porcine hair follicles","volume":"95","author":"Mathes","year":"2016","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.addr.2025.115703_bb0910","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jconrel.2016.08.007","article-title":"The role of tight junctions in skin barrier function and dermal absorption","volume":"242","author":"B\u00e4sler","year":"2016","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb0915","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3390\/pharmaceutics12070684","article-title":"Skin barriers in dermal drug delivery: which barriers have to be overcome and how can we measure them?","volume":"12","author":"Gorzelanny","year":"2020","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb0920","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1021\/acsbiomaterials.4c00570","article-title":"A novel 3D printed model of infected human hair follicles to demonstrate targeted delivery of Nanoantibiotics","volume":"10","author":"Aliyazdi","year":"2024","journal-title":"ACS Biomater Sci. Eng."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0925","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jid.2019.05.028","article-title":"Nanoparticle targeting to scalp hair follicles: new perspectives for a topical therapy for alopecia areata","volume":"140","author":"Christmann","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb0930","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/vde.12325","article-title":"Penetration of topically applied nanocarriers into the hair follicles of dog and rat dorsal skin and porcine ear skin","volume":"27","author":"Knorr","year":"2016","journal-title":"Vet. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0935","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.nano.2014.08.009","article-title":"Efficient nanoparticle-mediated needle-free transcutaneous vaccination via hair follicles requires adjuvantation","volume":"11","author":"Mittal","year":"2015","journal-title":"Nanomedicine"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0940","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jconrel.2010.11.015","article-title":"Selective follicular targeting by modification of the particle sizes","volume":"150","author":"Patzelt","year":"2011","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0945","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4155\/tde.14.61","article-title":"Delivery and targeting of nanoparticles into hair follicles","volume":"5","author":"Fang","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.addr.2025.115703_bb0950","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106476","article-title":"A comprehensive review on novel targeted therapy methods and nanotechnology-based gene delivery systems in melanoma","volume":"187","author":"Rahimi","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb0955","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/biomedicines8030060","article-title":"Viral vector-based melanoma gene therapy","volume":"8","author":"Hromic-Jahjefendic","year":"2020","journal-title":"Biomedicines"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb0960","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e29898","article-title":"Lipid-based nanoparticles as a promising treatment for the skin cancer","volume":"10","author":"Golestani","year":"2024","journal-title":"Heliyon"},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115703_bb0965","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijpharm.2018.10.043","article-title":"Coated microneedles mediated intradermal delivery of octaarginine\/BRAF siRNA nanocomplexes for anti-melanoma treatment","volume":"553","author":"Ruan","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb0970","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.3390\/ijms18102120","article-title":"Effects of extremely low frequency electromagnetic fields on melanogenesis through p-ERK and p-SAPK\/JNK pathways in human melanocytes","volume":"18","author":"Kim","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb0975","doi-asserted-by":"crossref","DOI":"10.1111\/jocd.16780","article-title":"Epigenetic modifications and the role of medical lasers in enhancing skin regeneration","volume":"24","author":"Haykal","year":"2025","journal-title":"J. Cosmet. Dermatol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb0980","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/lsm.23663","article-title":"Laser-assisted drug delivery of synthetic alpha melanocyte stimulating hormone and L-tyrosine leads to increased pigmentation area and expression of melanogenesis genes in a porcine hypertrophic scar model","volume":"55","author":"Carney","year":"2023","journal-title":"Lasers Surg. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0985","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1248\/bpb.b22-00746","article-title":"Use of iontophoresis technology for transdermal delivery of a minimal mRNA vaccine as a potential melanoma therapeutic","volume":"46","author":"Husseini","year":"2023","journal-title":"Biol. Pharm. Bull."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb0990","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ijpharm.2017.03.087","article-title":"Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles","volume":"525","author":"Labala","year":"2017","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb0995","doi-asserted-by":"crossref","DOI":"10.1002\/smsc.202300126","article-title":"Iontophoresis-driven microneedle arrays delivering transgenic outer membrane vesicles in program that stimulates transcutaneous vaccination for Cancer immunotherapy","volume":"3","author":"Wang","year":"2023","journal-title":"Small Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1000","series-title":"AIP Conference Proceedings","doi-asserted-by":"crossref","DOI":"10.1063\/1.3131463","article-title":"Noninvasive drug delivery using ultrasound: Targeting melanoma using siRNA against mutant (V600E) B-Raf","author":"Tran","year":"2009"},{"issue":"18","key":"10.1016\/j.addr.2025.115703_bb1005","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1158\/0008-5472.CAN-07-6614","article-title":"Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development","volume":"68","author":"Tran","year":"2008","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1010","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000509879","article-title":"Importance of microRNAs in skin oncogenesis and their suitability as agents and targets for topical therapy","volume":"33","author":"Gerloff","year":"2020","journal-title":"Skin Pharmacol. Physiol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1015","article-title":"Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy","volume":"2011","author":"Guo","year":"2011","journal-title":"J. Nanomater."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1020","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1021\/acsptsci.4c00419","article-title":"PEGylation-dependent cell uptake of lipid nanoparticles revealed by spatiotemporal correlation spectroscopy","volume":"7","author":"Digiacomo","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1025","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1093\/nar\/gkn115","article-title":"Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis","volume":"36","author":"Alam","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"51","key":"10.1016\/j.addr.2025.115703_bb1030","doi-asserted-by":"crossref","first-page":"32370","DOI":"10.1073\/pnas.2016158117","article-title":"Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency","volume":"117","author":"Patutina","year":"2020","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1035","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1073\/pnas.1813376116","article-title":"Mesyl phosphoramidate antisense oligonucleotides as an alternative to phosphorothioates with improved biochemical and biological properties","volume":"116","author":"Miroshnichenko","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"47","key":"10.1016\/j.addr.2025.115703_bb1040","doi-asserted-by":"crossref","DOI":"10.1002\/smll.201803002","article-title":"Worm-like biomimetic nanoerythrocyte carrying siRNA for melanoma gene therapy","volume":"14","author":"Wang","year":"2018","journal-title":"Small"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1045","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"21","key":"10.1016\/j.addr.2025.115703_bb1050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111596","article-title":"ncRNAs in therapeutics: challenges and limitations in nucleic acid-based drug delivery","volume":"22","author":"Hueso","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb1055","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejpb.2018.05.034","article-title":"The proton sponge hypothesis: fable or fact?","volume":"129","author":"Vermeulen","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.addr.2025.115703_bb1065","doi-asserted-by":"crossref","first-page":"115446","DOI":"10.1016\/j.addr.2024.115446","article-title":"Breaking the final barrier: evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosome","volume":"214","author":"Mrksich","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115703_bb1070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbpa.2024.102506","article-title":"Strategies and mechanisms for endosomal escape of therapeutic nucleic acids","volume":"81","author":"Grau","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1075","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.bioconjchem.8b00778","article-title":"Overcoming endosomal entrapment in drug delivery","volume":"30","author":"Pei","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.addr.2025.115703_bb1080","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115047","article-title":"Get out or die trying: peptide-and protein-based endosomal escape of RNA therapeutics","volume":"200","author":"Klipp","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.addr.2025.115703_bb1085","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104511118","article-title":"DNA-inspired nanomaterials for enhanced endosomal escape","volume":"118","author":"Lee","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1090","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.jconrel.2015.09.017","article-title":"Nucleic acid delivery into skin for the treatment of skin disease: proofs-of-concept, potential impact, and remaining challenges","volume":"219","author":"Zakrewsky","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1095","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.phrs.2017.06.008","article-title":"Drug delivery to melanoma brain metastases: can current challenges lead to new opportunities?","volume":"123","author":"Gampa","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1100","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.3390\/ijms25084243","article-title":"Understanding the tumor microenvironment in melanoma patients with in-transit metastases and its impacts on immune checkpoint immunotherapy responses","volume":"25","author":"Tian","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1105","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.3390\/cancers12102870","article-title":"Tumor microenvironment: implications in melanoma resistance to targeted therapy and immunotherapy","volume":"12","author":"Falcone","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115703_bb1110","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s11912-008-0067-y","article-title":"Melanoma and the tumor microenvironment","volume":"10","author":"Villanueva","year":"2008","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb1115","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.addr.2025.115703_bb1120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cells13161383","article-title":"Molecular susceptibility and treatment challenges in melanoma","volume":"13","author":"Kolathur","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15430\/JCP.24.028","article-title":"Therapeutic strategies for drug-resistant melanoma and their clinical implications","volume":"30","author":"Huang","year":"2025","journal-title":"J. Cancer Prevent."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1130","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s13206-022-00052-5","article-title":"Advances in nanoparticles for effective delivery of RNA therapeutics","volume":"16","author":"Byun","year":"2022","journal-title":"Biochip J."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1135","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s42247-021-00236-z","article-title":"Silica-based nanomaterials as drug delivery tools for skin cancer (melanoma) treatment","volume":"4","author":"Trinh","year":"2021","journal-title":"Emerg. Mater."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1140","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.apsb.2024.09.009","article-title":"Advances and prospects of RNA delivery nanoplatforms for cancer therapy","volume":"15","author":"Attia","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"issue":"47","key":"10.1016\/j.addr.2025.115703_bb1145","doi-asserted-by":"crossref","first-page":"46664","DOI":"10.1021\/acsomega.4c06714","article-title":"Brief comparison of the efficacy of cationic and anionic liposomes as nonviral delivery systems","volume":"9","author":"Ochoa-S\u00e1nchez","year":"2024","journal-title":"ACS omega"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1150","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-23013-2","article-title":"Development of lipid nanoparticles and liposomes reference materials (II): cytotoxic profiles","volume":"12","author":"Syama","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1155","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00104-y","article-title":"Nanodelivery of nucleic acids","volume":"2","author":"Mendes","year":"2022","journal-title":"Nat. Rev. Methods Primers"},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1160","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.3390\/cimb44100341","article-title":"Lipid nanoparticles: a novel gene delivery technique for clinical application","volume":"44","author":"Mashima","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"issue":"15","key":"10.1016\/j.addr.2025.115703_bb1165","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1039\/D3NA00198A","article-title":"Strategies for targeted gene delivery using lipid nanoparticles and cell-derived nanovesicles","volume":"5","author":"Lee","year":"2023","journal-title":"Nanoscale Adv."},{"issue":"14","key":"10.1016\/j.addr.2025.115703_bb1170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25147794","article-title":"Clinical applications of exosomes: a critical review","volume":"25","author":"Lee","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1175","doi-asserted-by":"crossref","DOI":"10.1111\/aji.13329","article-title":"The emerging role of exosomes as novel therapeutics: biology, technologies, clinical applications, and the next","volume":"85","author":"Song","year":"2021","journal-title":"Am. J. Reprod. Immunol."},{"issue":"6478","key":"10.1016\/j.addr.2025.115703_bb1180","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb1185","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1007\/s12033-023-00679-1","article-title":"Application of cell penetrating peptides as a promising drug carrier to combat viral infections","volume":"65","author":"Khairkhah","year":"2023","journal-title":"Mol. Biotechnol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1190","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines. Signal transduction and targeted","volume":"10","author":"Xiao","year":"2025","journal-title":"Therapy"},{"key":"10.1016\/j.addr.2025.115703_bb1195","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.biopha.2018.09.097","article-title":"Cell penetrating peptides: a concise review with emphasis on biomedical applications","volume":"108","author":"Derakhshankhah","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1200","doi-asserted-by":"crossref","DOI":"10.3390\/polym11040745","article-title":"Polymeric nanoparticles in gene therapy: new avenues of design and optimization for delivery applications","volume":"11","author":"Rai","year":"2019","journal-title":"Polymers (Basel)"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1205","article-title":"Polymeric nanocarriers for therapeutic gene delivery","volume":"20","author":"Zhang","year":"2025","journal-title":"Asian J. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1210","article-title":"Current advances in niosomes applications for drug delivery and cancer treatment","volume":"23","author":"Moammeri","year":"2023","journal-title":"Mater. Today Bio."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16020223","article-title":"Niosomes: composition, formulation techniques, and recent Progress as delivery systems in Cancer therapy","volume":"16","author":"Liga","year":"2024","journal-title":"Pharmaceutics"},{"issue":"18","key":"10.1016\/j.addr.2025.115703_bb1220","doi-asserted-by":"crossref","first-page":"4169","DOI":"10.1039\/C8GC01120F","article-title":"Ionic liquids for the preparation of biopolymer materials for drug\/gene delivery: a review","volume":"20","author":"Chen","year":"2018","journal-title":"Green Chem."},{"key":"10.1016\/j.addr.2025.115703_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.115157","article-title":"Potentials of ionic liquids to overcome physical and biological barriers","volume":"204","author":"Beaven","year":"2024","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.addr.2025.115703_bb1230","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jconrel.2019.08.029","article-title":"Mechanistic study of transdermal delivery of macromolecules assisted by ionic liquids","volume":"311","author":"Qi","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1235","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.omtm.2020.07.015","article-title":"Barriers and strategies of cationic liposomes for Cancer gene therapy","volume":"18","author":"Liu","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1240","first-page":"72","article-title":"Application of cationic liposomes for delivery of nucleic acids","volume":"8","author":"Shim","year":"2013","journal-title":"Asian J. Pharm. Sci."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1245","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41417-023-00617-y","article-title":"Recent progress in exosome research: isolation, characterization and clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1250","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082380","article-title":"Exosome: a new player in translational nanomedicine","volume":"9","author":"Aheget","year":"2020","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1255","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3390\/biomedicines9050583","article-title":"Peptide-based nanoparticles for therapeutic nucleic acid delivery","volume":"9","author":"Boisgu\u00e9rin","year":"2021","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.addr.2025.115703_bb1265","first-page":"212","article-title":"Niosome as a promising tool for increasing the effectiveness of anti-inflammatory compounds","volume":"23","author":"Fadaei","year":"2024","journal-title":"EXCLI J."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1270","first-page":"101","article-title":"Ionic liquids: preparations and limitations","volume":"14","author":"Shamsuri","year":"2010","journal-title":"Makara J. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1275","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.04.038","article-title":"Topical delivery of siRNA into skin using ionic liquids","volume":"323","author":"Dharamdasani","year":"2020","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb1280","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.3390\/pharmaceutics13091365","article-title":"Cationic liposomes as vectors for nucleic acid and hydrophobic drug therapeutics","volume":"13","author":"Ewert","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115703_bb1285","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13346-016-0294-y","article-title":"Liposome size and charge optimization for intraarterial delivery to gliomas","volume":"6","author":"Joshi","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1290","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/nano8050270","article-title":"Cationic liposomes carrying siRNA: impact of lipid composition on physicochemical properties, cytotoxicity and endosomal escape","volume":"8","author":"Lechanteur","year":"2018","journal-title":"Nanomaterials"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1295","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/nano10020190","article-title":"Immunological and toxicological considerations for the design of liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials"},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb1300","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/biot.201400162","article-title":"Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma","volume":"9","author":"Resnier","year":"2014","journal-title":"Biotechnol. J."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1305","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijpharm.2011.06.031","article-title":"In vivo imaging of DNA lipid nanocapsules after systemic administration in a melanoma mouse model","volume":"423","author":"David","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.addr.2025.115703_bb1315","series-title":"Cytokine-Enhanced Vaccine and Suicide Non-Viral Gene Therapy in Advanced Metastatic Melanoma Patients: Two Case Reports","author":"Finocchiaro","year":"2020"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1320","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/sj.gt.3303072","article-title":"Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma","volume":"15","author":"Finocchiaro","year":"2008","journal-title":"Gene Ther."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1325","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.3390\/cancers15041106","article-title":"Immunotherapy in melanoma: recent advances and future directions","volume":"15","author":"Knight","year":"2023","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb1330","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1158\/1078-0432.CCR-18-1550","article-title":"Immunotherapy of melanoma: facts and hopes","volume":"25","author":"Weiss","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1335","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41467-024-45358-0","article-title":"Adjuvant dendritic cell therapy in stage IIIB\/C melanoma: the MIND-DC randomized phase III trial","volume":"15","author":"Bol","year":"2024","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1340","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41571-024-00859-1","article-title":"Dendritic cells as orchestrators of anticancer immunity and immunotherapy","volume":"21","author":"Heras-Murillo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.addr.2025.115703_bb1345","doi-asserted-by":"crossref","first-page":"386","DOI":"10.21037\/atm.2017.06.13","article-title":"Dendritic cell therapy in melanoma","volume":"5","author":"Alvarez-Dominguez","year":"2017","journal-title":"Annals Trans. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1350","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2011.11.034","article-title":"Novel cationic liposomes provide highly efficient delivery of DNA and RNA into dendritic cell progenitors and their immature offsets","volume":"160","author":"Markov","year":"2012","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1355","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2011.11.023","article-title":"Novel cholesterol spermine conjugates provide efficient cellular delivery of plasmid DNA and small interfering RNA","volume":"160","author":"Maslov","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1360","series-title":"Evaluation of the Safety and Tolerability of iv Administration of a Cancer Vaccine in Patients with Advanced Melanoma (Lipo-MERIT)","author":"BioNTech","year":"2025"},{"issue":"7607","key":"10.1016\/j.addr.2025.115703_bb1365","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"issue":"7823","key":"10.1016\/j.addr.2025.115703_bb1370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-024-03846-0","article-title":"Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study","volume":"485","author":"Forchhammer","year":"2024","journal-title":"Virchows Arch."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1380","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113207","article-title":"Melanoma spheroid-containing artificial dermis as an alternative approach to in vivo models","volume":"417","author":"Monico","year":"2022","journal-title":"Exp. Cell Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1385","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103058","article-title":"Protocol to generate scaffold-free, multicomponent 3D melanoma spheroid models for preclinical drug testing","volume":"5","author":"Angeli","year":"2024","journal-title":"STAR Protocols"},{"issue":"23","key":"10.1016\/j.addr.2025.115703_bb1390","doi-asserted-by":"crossref","first-page":"e3839","DOI":"10.21769\/BioProtoc.3839","article-title":"A 3D skin melanoma spheroid-based model to assess tumor-immune cell interactions","volume":"10","author":"Wagner","year":"2020","journal-title":"Bio-protocol"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1395","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3390\/cells11061026","article-title":"3D melanoma Cocultures as improved models for nanoparticle-mediated delivery of RNA to tumors","volume":"11","author":"Sch\u00e4fer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.addr.2025.115703_bb1400","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.2147\/IJN.S147759","article-title":"Co-delivery of Aurora-a inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy","author":"Duan","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115703_bb1405","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1410","doi-asserted-by":"crossref","first-page":"936","DOI":"10.3390\/polym14050936","article-title":"pH-responsive nanocarriers in cancer therapy","volume":"14","author":"AlSawaftah","year":"2022","journal-title":"Polymers"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1415","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3390\/nano10081613","article-title":"pH-responsive nanoparticles for cancer immunotherapy: a brief review","volume":"10","author":"Yan","year":"2020","journal-title":"Nanomaterials"},{"key":"10.1016\/j.addr.2025.115703_bb1420","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.855019","article-title":"pH-responsive polymer nanomaterials for tumor therapy","volume":"12","author":"Chu","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s42003-020-0817-4","article-title":"pH-responsive high stability polymeric nanoparticles for targeted delivery of anticancer therapeutics","volume":"3","author":"Palanikumar","year":"2020","journal-title":"Commun. Biol."},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb1430","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrc3298","article-title":"Evolutionary dynamics of carcinogenesis and why targeted therapy does not work","volume":"12","author":"Gillies","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1435","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nbt0696-760","article-title":"pH-sensitive, cationic liposomes: a new synthetic virus-like vector","volume":"14","author":"Budker","year":"1996","journal-title":"Nat. Biotechnol."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1440","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1021\/acsbiomaterials.5b00025","article-title":"Examples of tumor growth inhibition properties of liposomal formulations of pH-sensitive histidinylated cationic amphiphiles","volume":"1","author":"Garu","year":"2015","journal-title":"ACS Biomater Sci. Eng."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1445","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.jconrel.2013.06.019","article-title":"Design and evaluation of new pH-sensitive amphiphilic cationic lipids for siRNA delivery","volume":"171","author":"Malamas","year":"2013","journal-title":"J. Control. Release"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1450","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1039\/C5BM00479A","article-title":"Delivering anti-cancer drugs with endosomal pH-sensitive anti-cancer liposomes","volume":"4","author":"Moku","year":"2016","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep35223","article-title":"Simultaneous delivery of paclitaxel and Bcl-2 siRNA via pH-sensitive liposomal nanocarrier for the synergistic treatment of melanoma","volume":"6","author":"Reddy","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115703_bb1460","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.887770","article-title":"The potential impact of melanosomal pH and metabolism on melanoma","volume":"12","author":"You","year":"2022","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb1465","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37517","article-title":"Co-delivery of siRNA and cisplatin via electrospun Nanofibrous membranes for synergistic treatment of malignant melanoma","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.addr.2025.115703_bb1470","first-page":"1","article-title":"Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma Cancer cells","author":"Khabazian","year":"2021","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1475","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ijd.14850","article-title":"The role of integrins in melanoma: a review","volume":"59","author":"Arias-Mejias","year":"2020","journal-title":"Int. J. Dermatol."},{"issue":"21","key":"10.1016\/j.addr.2025.115703_bb1480","doi-asserted-by":"crossref","first-page":"9078","DOI":"10.1158\/0008-5472.CAN-08-2397","article-title":"Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA","volume":"68","author":"Villares","year":"2008","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1485","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.jid.5700539","article-title":"Quantitative analysis of melanocytic tissue array reveals inverse correlation between activator protein-2\u03b1 and protease-activated receptor-1 expression during melanoma progression","volume":"127","author":"Tellez","year":"2007","journal-title":"J. Invest. Dermatol."},{"issue":"21","key":"10.1016\/j.addr.2025.115703_bb1490","doi-asserted-by":"crossref","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-11-1432","article-title":"PAR-1 and thrombin: the ties that bind the microenvironment to melanoma metastasis","volume":"71","author":"Zigler","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.addr.2025.115703_bb1495","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111873","article-title":"The role of hypoxia-inducible factor-1alpha and its signaling in melanoma","volume":"141","author":"Malekan","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1500","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CMR.0000000000000258","article-title":"Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions","volume":"26","author":"Skinner","year":"2016","journal-title":"Melanoma Res."},{"key":"10.1016\/j.addr.2025.115703_bb1505","first-page":"991","article-title":"Insights into the therapeutic potential of hypoxia-inducible factor-1\u03b1 small interfering RNA in malignant melanoma delivered via folate-decorated cationic liposomes","author":"Chen","year":"2016","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.addr.2025.115703_bb1510","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.omtn.2020.04.003","article-title":"Skin delivery of siRNA using sponge spicules in combination with cationic flexible liposomes","volume":"20","author":"Liang","year":"2020","journal-title":"Mol. Therapy-Nucleic Acids"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1515","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1080\/1061186X.2016.1258567","article-title":"Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer","volume":"25","author":"Jose","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/j.addr.2025.115703_bb1520","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118817","article-title":"Transferosomes as nanocarriers for drugs across the skin: quality by design from lab to industrial scale","volume":"573","author":"Fern\u00e1ndez-Garc\u00eda","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1525","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1918","article-title":"Transferosomes as a transdermal drug delivery system: dermal kinetics and recent developments","volume":"16","author":"Matharoo","year":"2024","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"18","key":"10.1016\/j.addr.2025.115703_bb1530","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.3390\/ijms22189743","article-title":"Elastic and ultradeformable liposomes for transdermal delivery of active pharmaceutical ingredients (APIs)","volume":"22","author":"Souto","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1535","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.2147\/IJN.S138267","article-title":"Elastic liposomes as novel carriers: recent advances in drug delivery","author":"Hussain","year":"2017","journal-title":"Int. J. Nanomedicine"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1540","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0006-3495(03)74917-0","article-title":"Hydration-driven transport of deformable lipid vesicles through fine pores and the skin barrier","volume":"84","author":"Cevc","year":"2003","journal-title":"Biophys. J."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1545","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jconrel.2008.10.003","article-title":"Ultradeformable cationic liposomes for delivery of small interfering RNA (siRNA) into human primary melanocytes","volume":"133","author":"Geusens","year":"2009","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1550","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jconrel.2016.03.010","article-title":"Development of edge-activated liposomes for siRNA delivery to human basal epidermis for melanoma therapy","volume":"228","author":"Dorrani","year":"2016","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1555","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.3390\/molecules28031498","article-title":"A review of different types of liposomes and their advancements as a form of gene therapy treatment for breast cancer","volume":"28","author":"Tseu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.addr.2025.115703_bb1560","series-title":"An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)","author":"ModernaTX","year":"2019"},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb1565","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1158\/2159-8290.CD-24-0158","article-title":"T-cell responses to individualized neoantigen therapy mRNA-4157 (V940) alone or in combination with pembrolizumab in the phase 1 KEYNOTE-603 study","volume":"14","author":"Gainor","year":"2024","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1570","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.3390\/ijms21061930","article-title":"In vitro biophysical and biological characterization of lipid nanoparticles co-encapsulating oncosuppressors mir-199b-5p and mir-204-5p as potentiators of target therapy in metastatic melanoma","volume":"21","author":"Fattore","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1575","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41388-022-02547-9","article-title":"Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance","volume":"42","author":"Fattore","year":"2023","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1580","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102292","article-title":"Novel gene therapy for drug-resistant melanoma: synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers","volume":"35","author":"Saraswat","year":"2024","journal-title":"Mol. Therapy-Nucleic Acids"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1585","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/biom10020285","article-title":"Silencing of STAT3 via peptidomimetic LNP-mediated systemic delivery of RNAi downregulates PD-L1 and inhibits melanoma growth","volume":"10","author":"Ehexige","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb1590","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202001853","article-title":"Combinatory delivery of etoposide and siCD47 in a lipid polymer hybrid delays lung tumor growth in an experimental melanoma lung metastatic model","volume":"10","author":"Abdel-Bar","year":"2021","journal-title":"Adv. Healthc. Mater."},{"issue":"52","key":"10.1016\/j.addr.2025.115703_bb1595","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2313009120","article-title":"In situ production and secretion of proteins endow therapeutic benefit against psoriasiform dermatitis and melanoma","volume":"120","author":"Cheng","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1600","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/jid.2013.478","article-title":"Reduced MiR-675 in exosome in H19 RNA-related melanogenesis via MITF as a direct target","volume":"134","author":"Kim","year":"2014","journal-title":"J. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1605","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jdermsci.2019.02.001","article-title":"Exosomal miRNA derived from keratinocytes regulates pigmentation in melanocytes","volume":"93","author":"Liu","year":"2019","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1610","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.2147\/DDDT.S414758","article-title":"Dendritic cell-derived exosomes driven drug co-delivery biomimetic nanosystem for effective combination of malignant melanoma immunotherapy and gene therapy","author":"Lin","year":"2023","journal-title":"Drug Des. Devel. Ther."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1615","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102179","article-title":"Identification of film-based formulations that move mRNA lipid nanoparticles out of the freezer","volume":"35","author":"Doan","year":"2024","journal-title":"Mol. Ther.\u2013Nucleic Acids"},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb1620","doi-asserted-by":"crossref","first-page":"7509","DOI":"10.7150\/thno.77259","article-title":"Lipid nanoparticles for delivery of RNA therapeutics: current status and the role of in vivo imaging","volume":"12","author":"Jung","year":"2022","journal-title":"Theranostics"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1625","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/vaccines9040359","article-title":"Lipid-based nanoparticles in the clinic and clinical trials: from cancer nanomedicine to COVID-19 vaccines","volume":"9","author":"Thi","year":"2021","journal-title":"Vaccines"},{"issue":"50","key":"10.1016\/j.addr.2025.115703_bb1630","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309472120","article-title":"Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects","volume":"120","author":"Chen","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1635","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jid.2024.04.031","article-title":"RNA therapy for oncogenic NRAS-driven nevi induces apoptosis","volume":"145","author":"Bryant","year":"2025","journal-title":"J. Invest. Dermatol."},{"issue":"34","key":"10.1016\/j.addr.2025.115703_bb1640","doi-asserted-by":"crossref","first-page":"23289","DOI":"10.1021\/acsnano.4c06160","article-title":"Low-dose Mildronate-derived Lipidoids for efficient mRNA vaccine delivery with minimal inflammation side effects","volume":"18","author":"Liu","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115703_bb1645","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jconrel.2022.03.021","article-title":"Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy","volume":"345","author":"Liu","year":"2022","journal-title":"J. Control. Release"},{"issue":"23","key":"10.1016\/j.addr.2025.115703_bb1650","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-20-0472","article-title":"Intratumoral IL12 mRNA therapy promotes TH1 transformation of the tumor microenvironment","volume":"26","author":"Hewitt","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"47","key":"10.1016\/j.addr.2025.115703_bb1655","doi-asserted-by":"crossref","first-page":"32401","DOI":"10.1021\/acsnano.4c03518","article-title":"In situ tumor-infiltrating lymphocyte therapy by local delivery of an mRNA encoding membrane-anchored anti-CD3 single-chain variable fragment","volume":"18","author":"Yoon","year":"2024","journal-title":"ACS Nano"},{"key":"10.1016\/j.addr.2025.115703_bb1660","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2024.102518","article-title":"In situ engineering of mRNA-CAR T cells using spleen-targeted ionizable lipid nanoparticles to eliminate cancer cells","volume":"59","author":"Li","year":"2024","journal-title":"Nano Today"},{"key":"10.1016\/j.addr.2025.115703_bb1665","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2023.103020","article-title":"Advances in promoting chimeric antigen receptor T cell trafficking and infiltration of solid tumors","volume":"84","author":"Hong","year":"2023","journal-title":"Curr. Opin. Biotechnol."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1670","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr. Oncol. Rep."},{"issue":"28","key":"10.1016\/j.addr.2025.115703_bb1675","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1039\/C7TB00317J","article-title":"Head group configuration increases the biocompatibility of cationic lipids for nucleic acid delivery","volume":"5","author":"Gerile","year":"2017","journal-title":"J. Mater. Chem. B"},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb1680","doi-asserted-by":"crossref","first-page":"7638","DOI":"10.1021\/acsami.5b12144","article-title":"Design of highly potent lipid-functionalized peptidomimetics for efficient in vivo siRNA delivery","volume":"8","author":"Xiao","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"42","key":"10.1016\/j.addr.2025.115703_bb1685","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202407619","article-title":"Novel endogenous engineering platform for robust loading and delivery of functional mRNA by extracellular vesicles","volume":"11","author":"Zickler","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1690","series-title":"Seminars in cell & developmental biology","article-title":"Exosomes and their roles in immune regulation and cancer","author":"Greening","year":"2015"},{"key":"10.1016\/j.addr.2025.115703_bb1695","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13578-019-0282-2","article-title":"Exosomes: biogenesis, biologic function and clinical potential","volume":"9","author":"Zhang","year":"2019","journal-title":"Cell Biosci."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb1700","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a023754","article-title":"Genome-editing technologies: principles and applications","volume":"8","author":"Gaj","year":"2016","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.addr.2025.115703_bb1705","first-page":"1","article-title":"The evolution and history of gene editing technologies","volume":"178","author":"Randhawa","year":"2021","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb1710","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.actbio.2024.10.030","article-title":"A biodegradable lipid nanoparticle delivers a Cas9 ribonucleoprotein for efficient and safe in situ genome editing in melanoma","volume":"190","author":"Yang","year":"2024","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1715","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/nn4057269","article-title":"Cell-penetrating peptides: design, synthesis, and applications","volume":"8","author":"Copolovici","year":"2014","journal-title":"ACS Nano"},{"issue":"41","key":"10.1016\/j.addr.2025.115703_bb1720","doi-asserted-by":"crossref","first-page":"36092","DOI":"10.1021\/acsomega.2c03974","article-title":"Functionalized peptide-based nanoparticles for targeted cancer nanotherapeutics: a state-of-the-art review","volume":"7","author":"Sharma","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.addr.2025.115703_bb1725","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.bioactmat.2021.09.029","article-title":"Peptide-based nanomaterials: self-assembly, properties and applications","volume":"11","author":"Li","year":"2022","journal-title":"Bioactive Mater."},{"key":"10.1016\/j.addr.2025.115703_bb1730","series-title":"PDL1-Binding Peptide\/Anti-miRNA21 Conjugate as a Therapeutic Modality for PD-L1high Tumors and TAMs","first-page":"62","author":"Kim","year":"2022"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1735","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab052","article-title":"Phage display and other peptide display technologies","volume":"46","author":"Jaroszewicz","year":"2022","journal-title":"FEMS Microbiol. Rev."},{"issue":"13","key":"10.1016\/j.addr.2025.115703_bb1740","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.3390\/molecules29133002","article-title":"Phage display technology in biomarker identification with emphasis on non-cancerous diseases","volume":"29","author":"Sadraeian","year":"2024","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1745","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.biotechadv.2010.07.004","article-title":"Phage display: concept, innovations, applications and future","volume":"28","author":"Pande","year":"2010","journal-title":"Biotechnol. Adv."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep29159","article-title":"Topical and targeted delivery of siRNAs to melanoma cells using a fusion peptide carrier","volume":"6","author":"Ruan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.addr.2025.115703_bb1755","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jconrel.2014.01.006","article-title":"Topical delivery of siRNA into skin using SPACE-peptide carriers","volume":"179","author":"Chen","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1760","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jconrel.2014.12.006","article-title":"Peptides as skin penetration enhancers: mechanisms of action","volume":"199","author":"Kumar","year":"2015","journal-title":"J. Control. Release"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1765","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/adhm.201500634","article-title":"De novo design of skin-penetrating peptides for enhanced transdermal delivery of peptide drugs","volume":"5","author":"Menegatti","year":"2016","journal-title":"Adv. Healthc. Mater."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1770","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nbt1193","article-title":"Transdermal protein delivery by a coadministered peptide identified via phage display","volume":"24","author":"Chen","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.addr.2025.115703_bb1775","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2020.125171","article-title":"Arginine-rich peptide based nanoparticles with bridge-like structure: enhanced cell penetration and tumor therapy effect","volume":"395","author":"Yan","year":"2020","journal-title":"Chem. Eng. J."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb1780","doi-asserted-by":"crossref","first-page":"11159","DOI":"10.1021\/acsami.3c14908","article-title":"Cell-penetrating and enzyme-responsive peptides for targeted Cancer therapy: role of arginine residue length on cell penetration and in vivo systemic toxicity","volume":"16","author":"Ghaemi","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2025.115703_bb1785","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2015.12.017","article-title":"Non-invasive topical delivery of plasmid DNA to the skin using a peptide carrier","volume":"222","author":"Vij","year":"2016","journal-title":"J. Control. Release"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb1790","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1021\/acs.molpharmaceut.1c00316","article-title":"Treatment of melanoma by Nano-conjugate-delivered Wee1 siRNA","volume":"18","author":"Zhang","year":"2021","journal-title":"Mol. Pharm."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb1795","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1021\/bc200235q","article-title":"Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA","volume":"22","author":"Alam","year":"2011","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1800","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2021.140604","article-title":"Challenge to overcome current limitations of cell-penetrating peptides","volume":"1869","author":"Kim","year":"2021","journal-title":"Biochim. Biophys. Acta, Proteins Proteomics"},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1805","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1002\/psc.2672","article-title":"Cell penetration: scope and limitations by the application of cell-penetrating peptides","volume":"20","author":"Reissmann","year":"2014","journal-title":"J. Pept. Sci."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1810","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1038\/s41598-025-86130-8","article-title":"Advances and prospects of cell-penetrating peptides in tumor immunotherapy","volume":"15","author":"Yang","year":"2025","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb1815","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1820","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1809","article-title":"Nanoparticles for vaccine and gene therapy: overcoming the barriers to nucleic acid delivery","volume":"14","author":"Moll\u00e9","year":"2022","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.addr.2025.115703_bb1825","first-page":"10","article-title":"Polymeric nanoparticles-promising carriers for cancer therapy","author":"Xiao","year":"2022","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb1830","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179118","article-title":"Targeted delivery of drugs and genes using polymer Nanocarriers for Cancer therapy","volume":"22","author":"Xia","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1835","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.3390\/biomedicines11051307","article-title":"Recent advances in the polish research on polysaccharide-based nanoparticles in the context of various administration routes","volume":"11","author":"M\u0142ynek","year":"2023","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1840","doi-asserted-by":"crossref","DOI":"10.5812\/traumamon.23862","article-title":"Celox-coated gauze for the treatment of civilian penetrating trauma: a randomized clinical trial","volume":"20","author":"Hatamabadi","year":"2015","journal-title":"Trauma Mon."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1845","doi-asserted-by":"crossref","first-page":"812","DOI":"10.3390\/jpm13050812","article-title":"Efficacy and safety of Axiostat\u00ae hemostatic dressing in aiding manual compression closure of the femoral arterial access site in patients undergoing endovascular treatments: a preliminary clinical experience in two centers","volume":"13","author":"Minici","year":"2023","journal-title":"J. Personalized Med."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1850","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jemermed.2009.02.017","article-title":"Comparison of ChitoFlex\u00ae, CELOX\u2122, and QuikClot\u00ae in control of hemorrhage","volume":"41","author":"Devlin","year":"2011","journal-title":"J. Emerg. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1855","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ymthe.2023.11.021","article-title":"MiR126-targeted-nanoparticles combined with PI3K\/AKT inhibitor as a new strategy to overcome melanoma resistance","volume":"32","author":"Arasi","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.addr.2025.115703_bb1860","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2019.115143","article-title":"Chitosan-coated liposomes to stabilize and enhance transdermal delivery of indocyanine green for photodynamic therapy of melanoma","volume":"224","author":"Lee","year":"2019","journal-title":"Carbohydr. Polym."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb1865","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3390\/pharmaceutics13060890","article-title":"Cell-penetrating peptides: applications in tumor diagnosis and therapeutics","volume":"13","author":"Stiltner","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb1870","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.822","article-title":"The role of cell-penetrating peptides in potential anti-cancer therapy","volume":"12","author":"Zhou","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.addr.2025.115703_bb1875","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118847","article-title":"Codelivery of STAT3 and PD-L1 siRNA by hyaluronate-TAT trimethyl\/thiolated chitosan nanoparticles suppresses cancer progression in tumor-bearing mice","volume":"266","author":"Bastaki","year":"2021","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1880","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/0110-5558.72415","article-title":"Therapeutic and cosmeceutical potential of ethosomes: an overview","volume":"1","author":"Verma","year":"2010","journal-title":"J. Adv. Pharm. Technol. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1885","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3390\/membranes13020193","article-title":"Mannosylated-chitosan-coated andrographolide nanoliposomes for the treatment of hepatitis: in vitro and in vivo evaluations","volume":"13","author":"Metkar","year":"2023","journal-title":"Membranes"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1890","article-title":"Mannosylated-chitosan-coated andrographolide nanoliposomes for the treatment of hepatitis: In vitro and In Vivo evaluations","volume":"13","author":"Metkar","year":"2023","journal-title":"Membranes (Basel)"},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb1895","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14040830","article-title":"Add sugar to chitosan: Mucoadhesion and In vitro intestinal permeability of Mannosylated chitosan Nanocarriers","volume":"14","author":"Ejaz","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb1900","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1158\/1535-7163.MCT-05-0540","article-title":"Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB\/c mice bearing CT-26 carcinoma cells","volume":"5","author":"Kim","year":"2006","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb1905","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1021\/acsbiomaterials.4c00426","article-title":"Noninvasive transdermal administration of mRNA vaccines encoding multivalent neoantigens effectively inhibits melanoma growth","volume":"10","author":"Hou","year":"2024","journal-title":"ACS Biomater Sci. Eng."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1910","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/pharmaceutics14020341","article-title":"Ultrasound-responsive Nrf2-targeting siRNA-loaded nanobubbles for enhancing the treatment of melanoma","volume":"14","author":"Argenziano","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115703_bb1915","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2020.105641","article-title":"Enhancing anti-melanoma outcomes in mice using novel chitooligosaccharide nanoparticles loaded with therapeutic survivin-targeted siRNA","volume":"158","author":"Liu","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"issue":"24","key":"10.1016\/j.addr.2025.115703_bb1920","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1039\/D4CC06730D","article-title":"Phenylboronic acid-modified nanoparticles for cancer treatment","volume":"61","author":"Zhou","year":"2025","journal-title":"Chem. Commun."},{"key":"10.1016\/j.addr.2025.115703_bb1925","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fbioe.2020.00165","article-title":"How the lack of chitosan characterization precludes implementation of the safe-by-design concept","volume":"8","author":"Marques","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.addr.2025.115703_bb1930","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118999","article-title":"Analysis of clinical trials on biomaterial and therapeutic applications of chitosan: a review","volume":"278","author":"Kantak","year":"2022","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.addr.2025.115703_bb1935","doi-asserted-by":"crossref","first-page":"100040","DOI":"10.1016\/j.ntm.2024.100040","article-title":"Chitosan nanoparticle delivery systems: an effective approach to enhancing efficacy and safety of anticancer drugs","volume":"3","author":"Grewal","year":"2024","journal-title":"Nano TransMed"},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1940","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/mt.2013.135","article-title":"Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis","volume":"21","author":"Wang","year":"2013","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb1945","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3390\/pharmaceutics12100931","article-title":"Hyaluronic acid nanoparticles as nanomedicine for treatment of inflammatory diseases","volume":"12","author":"Rao","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.addr.2025.115703_bb1950","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.addr.2015.11.015","article-title":"Polysaccharide-based nanoparticles for theranostic nanomedicine","volume":"99","author":"Swierczewska","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1955","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jconrel.2013.08.015","article-title":"Incorporation of histone derived recombinant protein for enhanced disassembly of core-membrane structured liposomal nanoparticles for efficient siRNA delivery","volume":"172","author":"Wang","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1960","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2015.04.009","article-title":"Protamine\u2013oligonucleotide-nanoparticles: recent advances in drug delivery and drug targeting","volume":"75","author":"Scheicher","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb1965","doi-asserted-by":"crossref","first-page":"14576","DOI":"10.1021\/acsami.6b15347","article-title":"Bioreducible cross-linked hyaluronic acid\/calcium phosphate hybrid nanoparticles for specific delivery of siRNA in melanoma tumor therapy","volume":"9","author":"Zhou","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb1970","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2008.05.016","article-title":"Mechanistic investigation of poly (ethylene imine)-based siRNA delivery: disulfide bonds boost intracellular release of the cargo","volume":"130","author":"Breunig","year":"2008","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1975","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jconrel.2009.10.007","article-title":"Stability and cellular uptake of polymerized siRNA (poly-siRNA)\/polyethylenimine (PEI) complexes for efficient gene silencing","volume":"141","author":"Lee","year":"2010","journal-title":"J. Control. Release"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb1980","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1089\/nat.2011.0293","article-title":"Polymers in small-interfering RNA delivery","volume":"21","author":"Singha","year":"2011","journal-title":"Nucleic Acid Ther."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb1985","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jconrel.2011.07.035","article-title":"Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy","volume":"156","author":"Yang","year":"2011","journal-title":"J. Control. Release"},{"key":"10.1016\/j.addr.2025.115703_bb1990","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.2147\/IJN.S42440","article-title":"Low-weight polyethylenimine cross-linked 2-hydroxypopyl-\u03b2-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA","author":"Li","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"1\u20132","key":"10.1016\/j.addr.2025.115703_bb1995","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijpharm.2008.09.039","article-title":"Polymeric nanoparticles for siRNA delivery and gene silencing","volume":"367","author":"Patil","year":"2009","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb2000","doi-asserted-by":"crossref","first-page":"953","DOI":"10.3390\/polym10090953","article-title":"Inhibition of tumor growth via systemic siRNA delivery using reducible bile acid-conjugated polyethylenimine","volume":"10","author":"Yin","year":"2018","journal-title":"Polymers"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2005","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/polym12020445","article-title":"Integration of polylactide into polyethylenimine facilitates the safe and effective intracellular siRNA delivery","volume":"12","author":"Ding","year":"2020","journal-title":"Polymers"},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb2010","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.biomaterials.2009.11.003","article-title":"The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine","volume":"31","author":"Alshamsan","year":"2010","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.jsps.2018.05.018","article-title":"STAT3-siRNA induced B16. F10 melanoma cell death: more association with VEGF downregulation than p-STAT3 knockdown","volume":"26","author":"Alshamsan","year":"2018","journal-title":"Saudi Pharm. J."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1021\/mp8000815","article-title":"Formulation and delivery of siRNA by oleic acid and stearic acid modified polyethylenimine","volume":"6","author":"Alshamsan","year":"2009","journal-title":"Mol. Pharm."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2025","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1593\/tlo.11100","article-title":"STAT3 knockdown in B16 melanoma by siRNA lipopolyplexes induces bystander immune response in vitro and in vivo","volume":"4","author":"Alshamsan","year":"2011","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.addr.2025.115703_bb2030","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","article-title":"Polyethylenimine (PEI) in gene therapy: current status and clinical applications","volume":"362","author":"Casper","year":"2023","journal-title":"J. Control. Release"},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb2035","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/2326-6066.CIR-24-0333","article-title":"First-in-human clinical trial of vaccination with WDVAX, a dendritic cell activating scaffold incorporating autologous tumor cell lysate, in metastatic melanoma patients","volume":"13","author":"Hodi","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"599","key":"10.1016\/j.addr.2025.115703_bb2040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9772","article-title":"Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models","volume":"13","author":"Lin","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.addr.2025.115703_bb2050","author":"Open Label"},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb2055","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1111\/jocd.16535","article-title":"Novel injectable polypeptide nanoparticle encapsulated siRNA targeting TGF-\u03b21 and COX-2 for localized fat reduction I: preclinical in vitro and animal models","volume":"23","author":"Nestor","year":"2024","journal-title":"J. Cosmet. Dermatol."},{"issue":"46","key":"10.1016\/j.addr.2025.115703_bb2060","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.20869","article-title":"Simultaneous silencing of TGF-\u03b21 and COX-2 reduces human skin hypertrophic scar through activation of fibroblast apoptosis","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2065","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad059","article-title":"Codelivery of TGF\u03b2 and Cox2 siRNA inhibits HCC by promoting T-cell penetration into the tumor and improves response to immune checkpoint inhibitors","volume":"6","author":"Kim","year":"2024","journal-title":"NAR Cancer"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/cgt.2008.29","article-title":"Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts","volume":"15","author":"Leng","year":"2008","journal-title":"Cancer Gene Ther."},{"issue":"19","key":"10.1016\/j.addr.2025.115703_bb2075","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1038\/sj.gt.3301294","article-title":"Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes","volume":"7","author":"Chen","year":"2000","journal-title":"Gene Ther."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb2080","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/nar\/29.6.1334","article-title":"Branched co-polymers of histidine and lysine are efficient carriers of plasmids","volume":"29","author":"Chen","year":"2001","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2085","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/sj.cgt.7700831","article-title":"Small interfering RNA targeting Raf-1 inhibits tumor growth in vitro and in vivo","volume":"12","author":"Leng","year":"2005","journal-title":"Cancer Gene Ther."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb2090","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1093\/nar\/30.6.1338","article-title":"Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles","volume":"30","author":"Chen","year":"2002","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"10.1016\/j.addr.2025.115703_bb2095","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1039\/D4NA00363B","article-title":"Efficient siRNA delivery to murine melanoma cells via a novel genipin-based nano-polymer","volume":"6","author":"Della Pelle","year":"2024","journal-title":"Nanoscale Adv."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb2100","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/polym8110385","article-title":"Fluorescence imaging in genipin crosslinked chitosan\u2013poly (vinyl pyrrolidone) hydrogels","volume":"8","author":"Matcham","year":"2016","journal-title":"Polymers"},{"key":"10.1016\/j.addr.2025.115703_bb2105","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101194","article-title":"Targeting dual gene delivery nanoparticles overcomes immune checkpoint blockade induced adaptive resistance and regulates tumor microenvironment for improved tumor immunotherapy","volume":"38","author":"Feng","year":"2021","journal-title":"Nano Today"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2110","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nano.2009.12.001","article-title":"Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer","volume":"6","author":"Dutta","year":"2010","journal-title":"Nanomedicine"},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2115","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.1039\/C5RA15270D","article-title":"Dendrosome mediated topical gene silencing by PLK-1 specific siRNA: implication in treatment of skin cancer in mouse model","volume":"6","author":"Sherwani","year":"2016","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb2120","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1039\/C4NR05241B","article-title":"Topical gene silencing by iontophoretic delivery of an antisense oligonucleotide\u2013dendrimer nanocomplex: the proof of concept in a skin cancer mouse model","volume":"7","author":"Venuganti","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.addr.2025.115703_bb2125","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jconrel.2020.03.023","article-title":"Transdermal siRNA delivery by pH-switchable micelles with targeting effect suppress skin melanoma progression","volume":"322","author":"Wang","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2010.12.008","article-title":"NF-\u03baB, inflammation, and metabolic disease","volume":"13","author":"Baker","year":"2011","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/pharmaceutics12010064","article-title":"Anti-metastatic effects on melanoma via intravenous administration of anti-NF-\u03baB siRNA complexed with functional peptide-modified nano-micelles","volume":"12","author":"Ibaraki","year":"2020","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2140","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1021\/jacs.0c12044","article-title":"Spherical nucleic acids for topical treatment of hyperpigmentation","volume":"143","author":"Fang","year":"2021","journal-title":"J. Am. Chem. Soc."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb2145","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.drudis.2022.02.005","article-title":"Recent advances in developing polymeric micelles for treating cancer: breakthroughs and bottlenecks in their clinical translation","volume":"27","author":"Kaur","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb2150","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.3390\/pharmaceutics15112622","article-title":"Advances in polymeric micelles: responsive and targeting approaches for cancer immunotherapy in the tumor microenvironment","volume":"15","author":"Cheng","year":"2023","journal-title":"Pharmaceutics"},{"issue":"17","key":"10.1016\/j.addr.2025.115703_bb2155","doi-asserted-by":"crossref","first-page":"9668","DOI":"10.3390\/ijms23179668","article-title":"Current advances in specialised niosomal drug delivery: manufacture, characterization and drug delivery applications","volume":"23","author":"Witika","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb2160","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/cbdd.12048","article-title":"Potent melanin production enhancement of human tyrosinase gene by tat and an entrapment in elastic cationic niosomes: potential application in vitiligo gene therapy","volume":"80","author":"Manosroi","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.addr.2025.115703_bb2165","series-title":"Melanoma","first-page":"621","article-title":"siRNA delivery to melanoma cells with cationic niosomes","author":"Obeid","year":"2021"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2170","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/08982104.2018.1531424","article-title":"Proof of concept studies for siRNA delivery by nonionic surfactant vesicles: in vitro and in vivo evaluation of protein knockdown","volume":"29","author":"Obeid","year":"2019","journal-title":"J. Liposome Res."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2175","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1002\/jps.22104","article-title":"Enhancement of transdermal absorption, gene expression and stability of tyrosinase plasmid (pMEL34)-loaded elastic cationic niosomes: potential application in vitiligo treatment","volume":"99","author":"Manosroi","year":"2010","journal-title":"J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.addr.2025.115703_bb2180","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.2042-7158.2012.01509.x","article-title":"Enhancement of gene expression and melanin production of human tyrosinase gene loaded in elastic cationic niosomes","volume":"64","author":"Khositsuntiwong","year":"2012","journal-title":"J. Pharm. Pharmacol."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2185","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10717544.2013.838077","article-title":"Recent advances in non-ionic surfactant vesicles (niosomes): self-assembly, fabrication, characterization, drug delivery applications and limitations","volume":"21","author":"Abdelkader","year":"2014","journal-title":"Drug Deliv."},{"issue":"01","key":"10.1016\/j.addr.2025.115703_bb2190","doi-asserted-by":"crossref","first-page":"179","DOI":"10.30574\/gscbps.2024.29.1.0341","article-title":"Niosomes: a promising approach for targeted drug delivery","volume":"29","author":"Deulkar","year":"2024","journal-title":"GSC Biol. Pharm. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb2195","doi-asserted-by":"crossref","unstructured":"M. Matczuk, et al., Ionic liquid-mediated drug delivery: a review on progress and challenges focused on poly (ionic liquid) nanoplatforms, J. Mol. Liq. 399 (2024)124403.","DOI":"10.1016\/j.molliq.2024.124403"},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2200","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1039\/D4BM01159G","article-title":"An ionic liquid-based delivery system of small interfering RNA targeting Bcl-2 for melanoma therapy","volume":"13","author":"Xing","year":"2025","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.addr.2025.115703_bb2205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jconrel.2016.09.003","article-title":"Therapeutic RNAi robed with ionic liquid moieties as a simple, scalable prodrug platform for treating skin disease","volume":"242","author":"Zakrewsky","year":"2016","journal-title":"J. Control. Release"},{"issue":"23\u201324","key":"10.1016\/j.addr.2025.115703_bb2210","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.drudis.2010.09.006","article-title":"Lyotropic liquid crystal systems in drug delivery","volume":"15","author":"Guo","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.addr.2025.115703_bb2215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-017-2330-0","article-title":"In vitro TyRP-1 knockdown based on siRNA carried by liquid crystalline nanodispersions: an alternative approach for topical treatment of vitiligo","volume":"35","author":"Tofani","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.addr.2025.115703_bb2220","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.136027","article-title":"Ionic liquid combined with cationic liposome co-delivers microphthalmia-associated transcription factor small interfering RNA to regulate melanogenesis","volume":"281","author":"Bai","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"28","key":"10.1016\/j.addr.2025.115703_bb2225","doi-asserted-by":"crossref","first-page":"33299","DOI":"10.1021\/acsami.3c03900","article-title":"Non-invasive transdermal delivery of antisense oligonucleotides with biocompatible ionic liquids","volume":"15","author":"Toyofuku","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"16","key":"10.1016\/j.addr.2025.115703_bb2230","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.3390\/cancers15164125","article-title":"Adjuvant therapy for high-risk melanoma: an in-depth examination of the state of the field","volume":"15","author":"Eljilany","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.addr.2025.115703_bb2235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102848","article-title":"Local administration of immunotherapy for patients with skin cancer: a systematic review","volume":"131","author":"Janssen","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.addr.2025.115703_bb2240","article-title":"Systemic adjuvant therapy for high-risk cutaneous melanoma","volume":"14","author":"Kobeissi","year":"2022","journal-title":"Therap. Adv. Med. Oncol."},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb2245","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41591-023-02583-2","article-title":"Adjuvant nivolumab in resected stage IIB\/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial","volume":"29","author":"Kirkwood","year":"2023","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2250","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/diseases6020042","article-title":"Viral vectors in gene therapy","volume":"6","author":"Lundstrom","year":"2018","journal-title":"Diseases"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb2255","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1021\/acsami.7b14362","article-title":"Melanocortin-1 receptor-targeting ultrasmall silica nanoparticles for dual-modality human melanoma imaging","volume":"10","author":"Chen","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb2260","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3390\/pharmaceutics12070649","article-title":"Silica-based gene delivery systems: from design to therapeutic applications","volume":"12","author":"Carvalho","year":"2020","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb2265","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1021\/acs.molpharmaceut.1c00510","article-title":"Efficient delivery of chlorin e6 by polyglycerol-coated iron oxide nanoparticles with conjugated doxorubicin for enhanced photodynamic therapy of melanoma","volume":"18","author":"Li","year":"2021","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb2270","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.det.2007.06.005","article-title":"Melanocyte receptors: clinical implications and therapeutic relevance","volume":"25","author":"Carlson","year":"2007","journal-title":"Dermatol. Clin."},{"issue":"7","key":"10.1016\/j.addr.2025.115703_bb2275","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202000115","article-title":"Engineered protein Nanocages for targeted and enhanced dermal melanocyte cellular uptake","volume":"1","author":"Bhaskar","year":"2021","journal-title":"Adv. NanoBiomed Res."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2280","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15142-w","article-title":"Specific targeting of melanotic cells with peptide ligated photosensitizers for photodynamic therapy","volume":"7","author":"Bigliardi","year":"2017","journal-title":"Sci. Rep."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb2285","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/exd.13856","article-title":"Regulation of melanocyte stem cells in the pigmentation of skin and its appendages: biological patterning and therapeutic potentials","volume":"28","author":"Qiu","year":"2019","journal-title":"Exp. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2295","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/969618","article-title":"Surgical approaches to create murine models of human wound healing","volume":"2011","author":"Wong","year":"2011","journal-title":"Biomed. Res. Int."},{"issue":"8","key":"10.1016\/j.addr.2025.115703_bb2300","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.immuni.2022.07.008","article-title":"Standing on the shoulders of mice","volume":"55","author":"Medetgul-Ernar","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2305","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6051210","article-title":"Human organ-specific 3D cancer models produced by the stromal self-assembly method of tissue engineering for the study of solid tumors","volume":"2020","author":"Roy","year":"2020","journal-title":"Biomed. Res. Int."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb2310","doi-asserted-by":"crossref","first-page":"10090","DOI":"10.1080\/21655979.2022.2063651","article-title":"Simple and robust 3D bioprinting of full-thickness human skin tissue","volume":"13","author":"Liu","year":"2022","journal-title":"Bioengineered"},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb2315","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.jid.2024.04.032","article-title":"Targeting the complexity of in vitro skin models: a review of cutting-edge developments","volume":"144","author":"Qu\u00edlez","year":"2024","journal-title":"J. Invest. Dermatol."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2320","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s12967-024-05113-x","article-title":"Melanocytes in regenerative medicine applications and disease modeling","volume":"22","author":"Coutant","year":"2024","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2325","doi-asserted-by":"crossref","first-page":"794","DOI":"10.3390\/biomedicines11030794","article-title":"Modelling the complexity of human skin in vitro","volume":"11","author":"Hofmann","year":"2023","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.addr.2025.115703_bb2330","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.1021\/acsbiomaterials.3c00283","article-title":"Layer-by-layer analysis of in vitro skin models","volume":"9","author":"Footner","year":"2023","journal-title":"ACS Biomater Sci. Eng."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2335","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40824-023-00415-5","article-title":"3D biofabrication of diseased human skin models in vitro","volume":"27","author":"Ahn","year":"2023","journal-title":"Biomater. Res."},{"key":"10.1016\/j.addr.2025.115703_bb2340","article-title":"Role of the tumor microenvironment in malignant melanoma organoids during the development and metastasis of tumors","volume":"11","author":"Zhou","year":"2023","journal-title":"Fronti. Cell Develop. Biol."},{"key":"10.1016\/j.addr.2025.115703_bb2345","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3389\/fonc.2019.00512","article-title":"The melding of drug screening platforms for melanoma","volume":"9","author":"Couto","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.addr.2025.115703_bb2350","article-title":"Current state of animal (mouse) modeling in melanoma research","volume":"8","author":"Kuzu","year":"2015","journal-title":"Cancer Growth Metastasis"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2355","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdermsci.2017.12.009","article-title":"Skin wound healing in humans and mice: challenges in translational research","volume":"90","author":"Zomer","year":"2018","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb2360","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ccell.2021.01.011","article-title":"Melanoma models for the next generation of therapies","volume":"39","author":"Patton","year":"2021","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.addr.2025.115703_bb2365","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.neo.2020.06.006","article-title":"BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases","volume":"22","author":"Grigore","year":"2020","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.addr.2025.115703_bb2370","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.356","article-title":"Braf V600E cooperates with Pten loss to induce metastatic melanoma","volume":"41","author":"Dankort","year":"2009","journal-title":"Nat. Genet."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2375","doi-asserted-by":"crossref","first-page":"101943","DOI":"10.1016\/j.xcrm.2025.101943","article-title":"Combined inhibition of focal adhesion kinase and RAF\/MEK elicits synergistic inhibition of melanoma growth and reduces metastases","volume":"6","author":"Almazan","year":"2025","journal-title":"Cell Rep. Med."},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-024-03234-1","article-title":"Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment","volume":"43","author":"Smith","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.addr.2025.115703_bb2385","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1755-148X.2010.00717.x","article-title":"Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a\/Arflox\/lox mice","volume":"23","author":"VanBrocklin","year":"2010","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"7424","key":"10.1016\/j.addr.2025.115703_bb2390","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/nature11624","article-title":"An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair\/fair skin background","volume":"491","author":"Mitra","year":"2012","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2395","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1172\/JCI72932","article-title":"Memory regulatory T cells reside in human skin","volume":"124","author":"Rodriguez","year":"2014","journal-title":"J. Clin. Invest."},{"issue":"12","key":"10.1016\/j.addr.2025.115703_bb2400","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"issue":"26","key":"10.1016\/j.addr.2025.115703_bb2405","doi-asserted-by":"crossref","first-page":"6867","DOI":"10.1016\/j.biomaterials.2010.05.027","article-title":"The systemic toxicity of positively charged lipid nanoparticles and the role of toll-like receptor 4 in immune activation","volume":"31","author":"Kedmi","year":"2010","journal-title":"Biomaterials"},{"issue":"3","key":"10.1016\/j.addr.2025.115703_bb2410","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1039\/C8TX00005K","article-title":"Correlation of the cytotoxic effects of cationic lipids with their headgroups","volume":"7","author":"Cui","year":"2018","journal-title":"Toxicol. Res."},{"issue":"2","key":"10.1016\/j.addr.2025.115703_bb2415","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0005-2736(97)00126-0","article-title":"Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells","volume":"1329","author":"Filion","year":"1997","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"issue":"38","key":"10.1016\/j.addr.2025.115703_bb2420","doi-asserted-by":"crossref","first-page":"32006","DOI":"10.1021\/acsami.8b12393","article-title":"Hyaluronan reduces cationic liposome-induced toxicity and enhances the antitumor effect of targeted gene delivery in mice","volume":"10","author":"Qian","year":"2018","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.addr.2025.115703_bb2425","article-title":"Effect of the amount of cationic lipid used to complex siRNA on the cytotoxicity and proinflammatory activity of siRNA-solid lipid nanoparticles","volume":"6","author":"Hanafy","year":"2023","journal-title":"Int. J. Pharm.: X"},{"issue":"1","key":"10.1016\/j.addr.2025.115703_bb2430","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40824-020-00190-7","article-title":"Recent advances in polymeric drug delivery systems","volume":"24","author":"Sung","year":"2020","journal-title":"Biomater. Res."},{"issue":"6","key":"10.1016\/j.addr.2025.115703_bb2435","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3390\/polym16060843","article-title":"Polymer-based drug delivery systems for cancer therapeutics","volume":"16","author":"Ding","year":"2024","journal-title":"Polymers"}],"container-title":["Advanced Drug Delivery Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169409X25001887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:05:02Z","timestamp":1780549502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169409X25001887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":482,"alternative-id":["S0169409X25001887"],"URL":"https:\/\/doi.org\/10.1016\/j.addr.2025.115703","relation":{},"ISSN":["0169-409X"],"issn-type":[{"value":"0169-409X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advances in gene delivery for melanocyte-associated disorders","name":"articletitle","label":"Article Title"},{"value":"Advanced Drug Delivery Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.addr.2025.115703","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115703"}}